Speaker

Michael Hamilton

Scientist II, Vividion Therapeutics

Michael Hamilton, Scientist II at Vividion Therapeutics, spoke at 8th RAS-Targeted Drug Development Summit (Boston, United States of America, 8–10 Sept 2026) in the session “Disruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies”.

Conferences: 1
Keynotes: 0
Upcoming: 0

Pharmacy & Pharmaceutical Sciences

Past appearances

8th RAS-Targeted Drug Development Summit
8–10 Sept 2026Boston, United States of America
- SpeakerDisruption of the RAS-PI3Kα Interaction Provides Enhanced Efficacy in Combination Mutant KRAS Targeting Therapies

More speakers at 8th RAS-Targeted Drug Development Summit

Luke Pase
Chief Technology Officer, Anocca AB
Nagi Ayad
Professor, Georgetown University
Stephanie Braun
Executive Director & Head of Enzalutamide, Medical Affairs (US), Astellas Pharma
Silvia Coma
Senior Director, Translational & Preclinical Research, Verastem, inc
Peter DeMuth
Chief Scientific Officer, Elicio Therapeutics
Matthew Farren
Senior Research, Pharmacology Investigator, Incyte Corporation

See all 32 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Michael Hamilton, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].